期刊
DRUGS & THERAPY PERSPECTIVES
卷 38, 期 3, 页码 112-126出版社
SPRINGERNATURE
DOI: 10.1007/s40267-022-00897-8
关键词
-
There are numerous treatments available for COVID-19, including small molecule antiviral agents such as remdesivir, molnupiravir, and nirmatrelvir-ritonavir. Many other small molecule antiviral agents are also being studied in clinical trials for their therapeutic potential.
Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although most are not well established; among these are several small molecule antiviral agents. Intravenous remdesivir is an established treatment worldwide for inpatients and in some countries is also available for use in non-hospitalised high risk patients to prevent progression to severe disease and hospitalization. Oral molnupiravir and oral nirmatrelvir-ritonavir are also available in several countries to prevent progression to severe disease and hospitalization for high-risk outpatients. Many other antiviral small molecules that may have therapeutic potential are under investigation in clinical trials. This article provides a summary of key molecular targets, pharmacology and preliminary data on the efficacy and safety of small molecule antiviral agents being investigated for the treatment of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据